Skip to main content

Table 1 Summary of systematic reviews included in the Evidence Mapping

From: Evidence mapping based on systematic reviews of therapeutic interventions for gastrointestinal stromal tumors (GIST)

ID

Study design

Search methods and years

Research question or aim

Number of studies included

Type of study

Population/Type of GIST

Patients (N)

AMSTAR Score

RCT

NRT

NCS

Cohort

CC

SC

Abdel-Rahman 2015

SR

Standard searcha; through July 2014.

To assess the available evidence for systemic therapy options for patients with advanced gastrointestinal stromal tumours beyond first-line imatinib.

26

6

0

15

5

0

0

Adults/Advanced GIST.

935

6

Chen 2014

SRM

Standard search; through June 2014.

To compare short-term and long-term results of patients undergoing laparoscopy surgery.

22

0

0

0

22

0

0

Adults/Localised GIST.

1166

9

Crona 2013

SR

Standard search; through August 2013.

To review the preclinical and clinical literature that led to the approval of regorafenib and to examine its place in therapy for the treatment of mCRC and GIST.

2

1

0

1

0

0

0

Adults/Advanced, unresectable and/or metastatic GIST.

233

5

Cirocchi 2010

SRM

Followed Cochrane Collaboration metodology; through June 2009.

To compare surgery alone with the use of imatinib as preoperative supplement for unresectable and/or metastatic GIST.

0

0

0

0

0

0

0

Adults/Unresectable and/or metastatic GIST.

901a

6

Essat 2011

SR

Standard search; through August 2009.

To evaluate the efficacy and safety of imatinib for the adjuvant treatment of adult patients with localised KIT (CD117)-positive GIST after complete surgical resection relative to current standard treatment (surgery without adjuvant therapy).

16

1

0

3

3

0

9

Adults/Localised GIST.

730

7

Hislop 2011/2012

SR

Standard search; through October 2010.

To determine the relative benefit (in patients who have acquired resistance to the 400 mg/day imatinib dose) of dose escalation (to either 600 mg/day or 800 mg/day imatinib), sunitinib or best supportive care.

5

3

1

0

1

0

0

Adults/ Unresectable and/or metastatic GIST.

669

9

Liang 2013

SRM

Standard search; through June 2012.

To compare surgical and oncologic outcomes of patients with GISTs undergoing laparoscopic resection surgery and open resection surgery.

17

0

0

0

17

0

0

Adults/Localised GIST.

776

10

Liu 2013

SRM

Standard search; through June 2012.

The current meta-analysis aimed to determine the efficacy and safety of different doses of imatinib in patients with GISTs and to identify the optimized dose, and to weigh the clinical benefit against the associated toxicity.

5

5

0

0

0

0

0

Adults/Unresectable and/or metastatic GIST.

2008

8

NICE 2009

SR

Standard search; through September 2008.

To consider the use of sunitinib malate for the treatment of people with unresectable and/or metastatic gastrointestinal stromal tumours (GIST) after failure of imatinib due to resistance or intolerance.

2

1

0

0

1

0

0

Adults/Unresectable and/or metastatic GIST.

1438

7

NICE 2014

SR

Standard search; through April 2014, updated on February 2014.

To consider the use of imatinib for the adjuvant treatment of gastrointestinal stromal tumours.

16

4

0

0

12

0

0

Adults/Unresectable and/or metastatic GIST.

2018

8

Ohtani 2013

SRM

Followed PRISMA recommendations; through June 2013.

To evaluate and compare the short- and long-term outcomes of laparoscopic and conventional open surgery for GIST.

12

0

0

0

12

0

0

Adults/Localized GIST.

644

8

Pelletier 2015

SRM

Standard search; through July 2012.

To compare the laparoscopic and open surgical resection of gastric GISTs to assess the effectiveness and safety of this minimally invasive technique.

7

0

0

0

6

1

0

Adults/Localized GIST.

330

10

Wilson 2005

SR

Standard search; through May 2003.

To assess the clinical and cost-effectiveness of imatinib in the treatment of unresectable and/or metastatic GISTs, relative to current standard treatments.

15

0

0

6

0

0

9

Adults/Unresectable and/or metastatic GIST.

1887

9

Wu 2014

SRM

Standard search; through February 2014.

To evaluate the efficacy of second-generation TKIs with regard to progression-free survival and overall survival in patients with advanced GIST.

3

3

0

0

0

0

0

Adults/Advanced GIST.

808

10

Yang 2012

SRM

Standard search; through February 2012.

To evaluate the efficacy and safety of two doses of imatinib for patients with GISTs.

5

5

0

0

0

0

0

Adults/Unresectable and/or metastatic GIST.

1861

7

Zheng 2014

SRM

Standard search; through May 2012.

To assess existing evidence about the efficacy and safety of laparoscopic resection versus that of open resection for gastric GISTs.

11

0

0

0

11

0

0

Adults/Localized GIST.

495

9

Zong 2011

SRM

Standard search; through July 2010.

To evaluate the response to imatinib at different dose levels to identify the better choice for the treatment of patients with GIST.

3

3

0

0

0

0

0

Adults/Unresectable and/or metastatic GIST.

1787

9

  1. aNo controlled or randomised clinical trials comparing surgery alone and use of imatinib as preoperative supplement were available when the SR was conducted. The authors performed a subgroup analysis in the patients receiving preoperative treatment with imatinib mesylate (N = 901)
  2. Standard search: Strategies documented in detail enough to be replicated
  3. RCT: Randomized controlled trial; NRT: Non-randomized trial; NCS: Non-controlled trial; CC: Case-control study; CS: case series